Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80802
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-964251
Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N0186
Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Lancet Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N038H
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Leukemia - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016 Manuscript - Primary Endpoint - Preliminary Analysis - Prevention - CALGB-70806
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-9741
Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). Atherton, P. , Burger, K. , Loprinzi, C. , Miller, R. , Jatoi, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N0993
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993) Atherton, Pamela J. , Burger, Kelli N. , Loprinzi, Charles L. ... - - Support Care Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N0993
The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591) Atherton, Pamela J. , Watkins-Bruner, Deborah W. , Gotay, Carolyn ... - - J Pain Symptom Manage - 2015 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - N0591
Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992) Atherton, Pamela J , Burger, Kelli N , Pederson, Levi D ... - - Clin Trials - 2016 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - N0992
Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903 Atkinson, Thomas M. , Halabi, Susan , Bennett, Antonia V. ... - - Pain Med - 2012 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70903
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 Baer, MR , George, SL , Sanford, BL , Mrózek, K , Kolitz, JE ... - - Leukemia - 2011 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9720
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance) Baggstrom, Maria Q. , Socinski, Mark A. , Wang, Xiaofei F. , Gu, Lin ... - - J Thorac Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607 , CALGB-70701
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99903
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D
Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101 Barginear, Myra , Dueck, Amylou C. , Allred, Jacob B. ... - - Oncologist - 2019 Manuscript - Primary Endpoint - Primary Analysis - Older Adult - A151411 , CALGB-40101 , CALGB-70301
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804 Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551 Bartlett, Nancy L. , Johnson, Jeffrey L. , Wagner-Johnston, Nina ... - - Cancer Chemother. Pharmacol. - 2009 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-9551
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50303
The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5) Barton, D. L. , Atherton, P. J. , Bauer, B. A. , Moore, D. F. Jr ... - - J Support Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N01C5
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. I. , Sloan, J. A. , Stawis, A. N. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9
A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9
Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2
Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. , Sloan, J. A. ... - - J. Natl. Cancer Inst. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2
Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7 Barton, D. L. , Moraska, A. R. , Sood, A. , Sloan, J. A. , Suh, J. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C7
Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - Support Care Cancer - 2013 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA Barton, D. L. , Soori, G. S. , Bauer, B. , Sloan, J. , Johnson, P. A. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA Barton, D. L. , Wos, E. J. , Qin, R. , Mattar, B. I. , Green, N. B. ... - - Support Care Cancer - 2011 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA
A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA Barton, D. L. , Wos, E. , Qin, R. , Mattar, B. , Green, N. , Lanier, K. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA
The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 Barton, Debra L. , Burger, Kelli , Novotny, Paul J. , Fitch, Tom R. ... - - Support Care Cancer - 2013 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N00C9
Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T. , Gill, Paula ... - - Support Care Cancer - 2018 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1
Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA Barton, Debra L. , Soori, Gamini S. , Bauer, Brent A. ... - - Support Care Cancer - 2010 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance) Barton, Debra L. , Thanarajasingam, Gita , Sloan, Jeff A. ... - - Cancer - 2014 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. Barton, Debra L , Wender, Donald B , Sloan, Jeff A , Dalton, Robert J ... - - J. Natl. Cancer Inst. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N02C3
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002) Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100002
Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper Bennett, Antonia V. , Keenoy, Kathleen , Shouery, Marwan ... - - Qual Life Res - 2016 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - NCT01458509
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NANETS - Pancreas - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - GI - C150705 , C89803 , C9581
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993 Manuscript - Primary Endpoint - Primary Analysis - Breast - C8743
Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105 Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Leuk. Lymphoma - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50206
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Cancer - 2006 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Lymphoma - CALGB-9153
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904
Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904 Bogart, Jeffrey A. , Hodgson, Lydia , Seagren, Stephen L. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-924652
Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance) Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153
The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - JAMA - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma. Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-Oncology - 2019 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-85-72-51
Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma. Breen, William G , Anderson, S Keith , Carrero, Xiomara W ... - - Neuro-oncology - 2020 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-86-72-51
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM) Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177
Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance) Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W. ... - - Neurooncol Pract - 2015 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-86-72-51
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases. Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases Brown, Paul D. , Jaeckle, Kurt , Ballman, Karla V. , Farace, Elana ... - - JAMA - 2016 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0177
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial Brown, Paul D , Ballman, Karla V , Cerhan, Jane H , Anderson, S Keith ... - - Lancet Oncol. - 2017 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer Bryce, Alan H. , Mattar, Bassam , Hillman, Shauna L. , Adjei, Alex A. ... - - Am. J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-0027
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. Buckner, Jan C , O'Fallon, Judith R , Dinapoli, Robert P ... - - J. Neurooncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-94-72-52
Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance) Burstein, Harold J. , Cirrincione, Constance T. , Barry, William T. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial Buzdar, Aman U , Suman, Vera J , Meric-Bernstam, Funda ... - - Lancet Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Byrd, John C , Peterson, Bercedis L , Rai, Kanti R , Hurd, David ... - - Leuk. Lymphoma - 2009 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19901
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib Carey, Lisa A. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40601
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - C40601
Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392) Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392
Phase 2 Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive-Stage Small Cell Lung Cancer, N0423 Chee, Cheng E. , Jett, James R. , Bernath, Albert M. ... - - Cancer - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0423
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB) Cheville, Andrea L. , Sloan, Jeff A. , Northfelt, Donald W. ... - - Support Care Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N01CB
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - GU - A031203
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial. Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial Civantos, Francisco J. , Zitsch, Robert P. , Schuller, David E. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803) Cohen, Harvey Jay , Lan, Lan , Archer, Laura ... - - J Geriatr Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70803
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett, Wendy R , McCall, Linda M , Petersen, Rebecca P ... - - J. Clin. Oncol. - 2006 Manuscript - Primary Endpoint - Primary Analysis - Experimental - Z0020
ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Croghan, Ivana T , Hurt, Richard D , Dakhil, Shaker R ... - - Mayo Clin. Proc. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Prevention - NCCTG-N99C4
N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy Crozier, Jennifer A. , Advani, Pooja P. , LaPlant, Betsy ... - - Clin. Breast Cancer - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0436
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Czuczman, M S , Leonard, J P , Jung, S , Johnson, J L , Hsi, E D ... - - Ann. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402 Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Czuczman, Myron S , Porcu, Pierluigi , Johnson, Jeffrey ... - - Leuk. Lymphoma - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59901
p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103
The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761 D'Cunha, J. , Wang, X. , Groth, S. S. , Vollmer, R. T. ... - IASLC (WCLC) - J Thorac Oncol - 2009 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9761
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 Damon, Lloyd E. , Johnson, Jeffrey L. , Niedzwiecki, Donna ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59909
Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715) Dao, Dyda , Zelma, Tyler , Jatoi, Aminah , Freedman, Rachel ... - ASCO - J Clin Oncol - 2018 Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151715 , C8541 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741 , N89-30-52 , N9831
Older‐Patient‐Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715) Dao, Dyda , Zemla, Tyler , Jatoi, Aminah , Freedman, Rachel A. ... - - Oncologist - 2019 Manuscript - Primary Endpoint - Primary Analysis - Older Adult - A151715 , CALGB-49907 , CALGB-40401
Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial Darling, G. , Allen, M. , Decker, P. , Ballman, K. , Landreneau, R. ... - AATS - American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less Than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial Darling, Gail E. , Allen, Mark S. , Decker, Paul A. , Ballman, Karla ... - - J. Thorac. Cardiovasc. Surg. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90004
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801 DeAngelo, Daniel J. , Yu, Daohai , Johnson, Jeffrey L. ... - - Blood - 2007 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19801
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Ann. Surg. - 2013 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - ACOSOG-Z9000
Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST) DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Lancet - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions Demmy, T. L. , Gu, L. , Burkhalter, J. , Toloza, E. M. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102
Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102) Demmy, Todd L. , Gu, Lin , Burkhalter, Jack E. , Toloza, Eric M. ... - - J Natl Compr Canc Netw - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102
Perceived Risk for Cancer Progression and Psychological Status in Chronic Lymphocytic Leukemia Patients: CALGB 70603 (Alliance) Deshields, Teresa , Dueck, Amylou C. , Rogers, Kerry ... - - Leuk. Lymphoma - 2019 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70603 , CALGB-10501
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 Devine, Steven M. , Owzar, Kouros , Blum, William , Mulkey, Flora ... - - J. Clin. Oncol - 2015 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William T. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma† Dickson, M. A. , Mahoney, M. R. , Tap, W. D. , D'Angelo, S. P. ... - - Ann. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091102
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102
Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087
Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis Ding, Wei , Shanafelt, Tait D. , Lesnick, Connie E. ... - - Br. J. Haematol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - N1087
The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013 Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087
Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion Dresler, Carolyn M. , Olak, Jemi , Herndon, James E. ... - - Chest - 2005 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9334
N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM) Dronca, R. , Perez, D. , Allred, J. , Maples, W. , Creagan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0675
Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma Dronca, Roxana S. , Allred, Jacob B. , Perez, Domingo G. ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0675
CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701
A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307 Dubey, Sarita , Jänne, Pasi A. , Krug, Lee , Pang, Herbert ... - - J Thorac Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30307
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM) Dudek, A. Z. , Kindler, H. L. , Otterson, G. A. , Pang, H. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report Dudek, A. Z. , Pang, H. , Kratzke, R. A. , Otterson, G. A. ... - - J Thorac Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601
Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901 Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901
Validity and Reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Dueck, Amylou C. , Mendoza, Tito R. , Mitchell, Sandra A. ... - - JAMA Oncol - 2015 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - NCT02158637
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Duggan, David B , Petroni, Gina R , Johnson, Jeffrey L ... - - J. Clin. Oncol. - 2003 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - C8952
Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial Dupuy, D. E. , Fernando, H. , Hillman, S. , Ng, T. , Tan, A. D. ... - CHEST - Chest - 2013 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033
Radiofrequency Ablation of Stage IA NSCLC in Medically Inoperable Patients: Results from the ACOSOG Z4033 (Alliance) Trial Dupuy, Damian E. , Fernando, Hiran C. , Hillman, Shauna , Ng, Thomas ... - - Cancer - 2015 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033
A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0528
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2) Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261 Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0326
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - N0144
A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528 Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0528
NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Cancer Chemother. Pharmacol. - 2015 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091103
A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Lancet Oncol. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091401
A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401
CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer Eastham, J.A. , Heller, G. , Halabi, S. ,
